Kepler Capital Maintained a Buy Rating on Genfit (GNFT)

Genfit S.A. (NASDAQ:GNFT) is one of the High Growth Penny Stocks That Are Profitable in 2025On July 8, Justine Telliez from Kepler Capital maintained a Buy rating on Genfit S.A. (NASDAQ:GNFT) with a price target of €8.40.

The rating comes after the company released its mid-year update on its liquidity contract with Credit Industriel et Commercial. The company noted that as of June 30, 2025, there were 201,000 shares in the liquidity account along with €398,484.67 in cash in liquidity. Moreover, the company also released details about its trading activity, which shows 1,412,901 shares were bought, 1,419,301 shares were sold, with the number of buy and sell trades standing at  2,673 and 1,894, respectively.

Kepler Capital Maintained a Buy Rating on Genfit (GNFT)

A biotechnologist in a laboratory wearing a lab coat, preparing samples for a clinical trial.

Genfit S.A. (NASDAQ:GNFT) is a French biopharmaceutical company that develops treatments and diagnostic tools for rare and serious liver diseases.

While we acknowledge the potential of GNFT to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than GNFT and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.